A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

This trial is testing the combination of adebrelimab (an immunotherapy drug) with chemotherapy and radiation therapy for patients with extensive-stage small cell lung cancer (SCLC) that has spread to only a few sites (called oligometastatic disease — 5 or fewer lesions in 3 or fewer organs), to see if this aggressive combined approach improves survival. **You may be eligible if...** - You are between 18 and 75 years old with confirmed extensive-stage small cell lung cancer - Your cancer has spread to 5 or fewer lesions in 3 or fewer organs (oligometastatic) - You have not previously received chemotherapy, radiation, or immunotherapy for this cancer - You have a good performance status (ECOG 0-1) and expected survival of at least 3 months **You may NOT be eligible if...** - Your cancer has spread extensively beyond 5 lesions or to more than 3 organs - You have cancer in the fluid around the brain (leptomeningeal disease) - You have uncontrolled fluid around the lungs or heart - You have had another cancer within the past 5 years Talk to your doctor to see if this trial is right for you.